Skip to main content
Equibles
CRDF logo

CRDF · Cardiff Oncology, Inc.

Track CRDF — free

Use CRDF with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CRDF

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.90 -0.06 (-6.10%) At close · Aug 17
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$71.36M
Shares
77.80M

Cardiff Oncology, Inc. Earnings Call Transcripts

Every quarterly earnings call for Cardiff Oncology, Inc. (CRDF) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲18.7% $92,576 −$4.24M '19 Q4 20-02-27 ▲9.6% $68,000 −$4.09M '20 Q1 20-05-07 ▲12.1% $43,000 −$4.12M '20 Q2 20-08-11 ▲163.1% $136,000 −$4.50M '20 Q3 20-11-05 ▲5.9% $72,000 −$5.18M '21 Q1 21-05-06 ▲11.8% $133,000 −$9.44M '21 Q4 22-02-24 ▲2.8% $74,000 −$10.99M '22 Q1 22-05-05 ▲8.1% $93,000 −$8.57M '22 Q3 22-11-03 ▼3.8% $128,000 −$8.70M '22 Q4 23-03-02 ▲51.6% $141,000 −$9.73M '23 Q3 23-11-02 ▲21.9% $156,000 −$9.34M '23 Q4 24-02-29 ▲147% $205,000 −$10.01M '24 Q1 24-05-02 ▲50.9% $163,000 −$11.78M '24 Q2 24-08-08 ▼3.8% $150,000 −$11.79M '24 Q4 25-02-27 ▼25.8% $121,000 −$13.94M '25 Q2 25-07-29 LATEST ▼62.4% $41,000 −$12.35M '26 Q1 26-06-03
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-06-03
Cardiff Oncology, Inc. Q1 FY2026 Earnings Call
Revenue
$41,000
▼ 62.4% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-01-27
Cardiff Oncology, Inc. Conference Call
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q2
2025-07-29
Cardiff Oncology, Inc. Q2 FY2025 Earnings Call
Revenue
$121,000
▼ 25.8% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Cardiff Oncology, Inc. Q4 FY2024 Earnings Call
Confident tone Lead mCRC program CRDF-004 / onvansertib efficacy Breast cancer preclinical program Comparative reference to Pfizer BREAKWATER
Revenue
$150,000*
▼ 3.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-08-08
Cardiff Oncology, Inc. Q2 FY2024 Earnings Call
Positive tone Lead mCRC program CRDF-004 Pancreatic cancer program pivot Additional cancer indications and preclinical work
Revenue
$163,000
▲ 50.9% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Cardiff Oncology, Inc. Q1 FY2024 Earnings Call
Confident tone First-line RAS-mutated mCRC lead program AACR 2024 data presentations RAS wild-type mCRC opportunity
Revenue
$205,000
▲ 147% YoY
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Cardiff Oncology, Inc. Q4 FY2023 Earnings Call
Confident tone ONSEMBLE trial randomized data release First-line mCRC program / CRDF-004 Pancreatic cancer program
Revenue
$156,000*
▲ 21.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Cardiff Oncology, Inc. Q3 FY2023 Earnings Call
Revenue
$141,000
▲ 51.6% YoY
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
Cardiff Oncology, Inc. Q4 FY2022 Earnings Call
Revenue
$128,000*
▼ 3.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Cardiff Oncology, Inc. Q3 FY2022 Earnings Call
Revenue
$93,000
▲ 8.1% YoY
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Cardiff Oncology, Inc. Q1 FY2022 Earnings Call
Revenue
$74,000
▲ 2.8% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Cardiff Oncology, Inc. Q4 FY2021 Earnings Call
Revenue
$133,000*
▲ 11.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q1
2021-05-06
Cardiff Oncology, Inc. Q1 FY2021 Earnings Call
Revenue
$72,000
▲ 5.9% YoY
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q3
2020-11-05
Cardiff Oncology, Inc. Q3 FY2020 Earnings Call
Revenue
$136,000
▲ 163.1% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-11
Cardiff Oncology, Inc. Q2 FY2020 Earnings Call
Revenue
$43,000
▲ 12.1% YoY
Diluted EPS
$-0.51
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Cardiff Oncology, Inc. Q1 FY2020 Earnings Call
Revenue
$68,000
▲ 9.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Cardiff Oncology, Inc. Q4 FY2019 Earnings Call
Revenue
$92,576*
▲ 18.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–18 of 18 earnings calls
Key facts CIK 1213037 CUSIP 14147L108 13F (30d) 98 filings 96 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)